Please login to the form below

Not currently logged in
Email:
Password:

Dr Steven Gillis joins Shire’s board of directors

He will sit on the pharma firm's science and technology and its remuneration committee

Steven Gillis - ShireShire has appointed managing director of Arch Venture Partners Dr Steven Gillis to its board of directors.

Dr Gillis will join the Ireland-based pharma firm on October 1, becoming a member of its science and technology committee as well as its remuneration committee.

Commenting on his appointment, he said: “Shire has a clear and ambitious patient-focused vision for the future and I look forward to the opportunity to help them achieve it.”

A trained immunologist, Dr Gillis has experience in the life sciences industry through his work at Arch, which provides venture capital to firms working on new life sciences technologies.

Prior to this role, Dr Gillis was a founder and director of Corixa Corporation, which was acquired by GlaxoSmithKline in 2005 (GSK), and he was previously a founder and director of Immunex Corporation.

He currently holds a number of other roles, including as a non-executive director of New Zealand-based biotech Genesis Research and Development Corporation.

10th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics